Castle Biosciences, Inc. (NASDAQ:CSTL - Get Free Report) insider Derek J. Maetzold sold 986 shares of the company's stock in a transaction dated Monday, January 13th. The shares were sold at an average price of $28.03, for a total transaction of $27,637.58. Following the transaction, the insider now directly owns 80,818 shares of the company's stock, valued at approximately $2,265,328.54. This trade represents a 1.21 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.
Shares of CSTL stock traded down $0.44 during mid-day trading on Wednesday, reaching $25.02. 541,633 shares of the company's stock traded hands, compared to its average volume of 634,804. The company's 50-day moving average price is $29.55 and its 200-day moving average price is $28.02. The company has a market cap of $700.81 million, a P/E ratio of 125.11 and a beta of 0.92. The company has a quick ratio of 7.64, a current ratio of 7.78 and a debt-to-equity ratio of 0.02. Castle Biosciences, Inc. has a 12 month low of $16.97 and a 12 month high of $35.84.
Castle Biosciences (NASDAQ:CSTL - Get Free Report) last posted its quarterly earnings data on Monday, November 4th. The company reported $0.08 EPS for the quarter, topping the consensus estimate of ($0.06) by $0.14. Castle Biosciences had a net margin of 1.95% and a return on equity of 1.47%. The business had revenue of $85.78 million for the quarter, compared to analyst estimates of $78.55 million. During the same quarter in the previous year, the firm posted ($0.26) earnings per share. On average, equities analysts expect that Castle Biosciences, Inc. will post 0.34 earnings per share for the current fiscal year.
A number of research analysts have commented on the company. Stephens reaffirmed an "overweight" rating and set a $41.00 price target on shares of Castle Biosciences in a research report on Thursday, January 2nd. BTIG Research upped their target price on Castle Biosciences from $35.00 to $40.00 and gave the company a "buy" rating in a report on Monday, October 14th. Canaccord Genuity Group lifted their price target on shares of Castle Biosciences from $35.00 to $42.00 and gave the company a "buy" rating in a report on Tuesday, October 29th. Robert W. Baird upped their price objective on shares of Castle Biosciences from $37.00 to $39.00 and gave the stock an "outperform" rating in a report on Tuesday, November 5th. Finally, Scotiabank lifted their target price on shares of Castle Biosciences from $37.00 to $44.00 and gave the company a "sector outperform" rating in a research note on Wednesday, November 6th. Seven research analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has a consensus rating of "Buy" and an average price target of $40.29.
Read Our Latest Stock Analysis on CSTL
A number of institutional investors and hedge funds have recently added to or reduced their stakes in CSTL. Point72 Asset Management L.P. boosted its stake in Castle Biosciences by 828.3% in the 3rd quarter. Point72 Asset Management L.P. now owns 499,192 shares of the company's stock worth $14,237,000 after purchasing an additional 445,415 shares in the last quarter. Marshall Wace LLP raised its holdings in Castle Biosciences by 116.5% in the second quarter. Marshall Wace LLP now owns 212,036 shares of the company's stock worth $4,616,000 after buying an additional 114,104 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. lifted its stake in shares of Castle Biosciences by 147.4% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 165,458 shares of the company's stock worth $4,719,000 after buying an additional 98,571 shares in the last quarter. Renaissance Technologies LLC grew its holdings in shares of Castle Biosciences by 47.3% during the second quarter. Renaissance Technologies LLC now owns 301,500 shares of the company's stock valued at $6,564,000 after buying an additional 96,800 shares during the last quarter. Finally, State Street Corp increased its position in shares of Castle Biosciences by 9.8% during the third quarter. State Street Corp now owns 680,001 shares of the company's stock valued at $19,394,000 after acquiring an additional 60,924 shares in the last quarter. Institutional investors own 92.60% of the company's stock.
Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Castle Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Castle Biosciences wasn't on the list.
While Castle Biosciences currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.